Please assess the completion status of the following clinical trial:

Trial Title: Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures~* Currently receiving FTC/RPV/TDF FDC for ≥ 6 consecutive months preceding the screening visit~* Documented plasma HIV-1 RNA levels \< 50 copies/mL (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is \> 50 copies/mL) for ≥ 6 months preceding the screening visit. After reaching HIV-1 RNA \< 50 copies/mL, single values of HIV-1 RNA ≥ 50 copies/mL followed by resuppression, are allowed~* Have no documented resistance to any of the study agents at any time in the past~* HIV-1 RNA \< 50 copies/mL at the screening visit~* Hepatic transaminases (AST and ALT) ≤ 5 × upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 mg/dL (≤ 26 μmol/L), or normal direct bilirubin~* Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm\^3 (1.00 GI/L); platelets ≥ 50,000/mm\^3 (50 GI/L); hemoglobin ≥ 8.5 g/dL (85 g/L))~* Serum amylase ≤ 5 × ULN (individuals with serum amylase \> 5 × ULN will remain eligible if serum lipase is ≤ 5 × ULN)~* Normal ECG (or if abnormal, determined by the Investigator to be not clinically significant)~* Adequate renal function: Estimated glomerular filtration rate ≥ 50 mL/min (1.17 mL/sec) according to the Cockcroft-Gault formula~Key Exclusion Criteria:~* Hepatitis B surface antigen (HBsAg) positive~* Hepatitis C antibody positive with detectable hepatitis C virus (HCV) RNA (individuals who have HCV antibody but no detectable HCV RNA are eligible to enroll)~* Individuals experiencing or with a medical history of decompensated cirrhosis (e.g., ascites, encephalopathy, etc.)~* Females who are breastfeeding~* Positive serum pregnancy test~* Current alcohol or substance use judged by the Investigator to potentially interfere with individual's study compliance~* A history of malignancy within the past 5 years (prior to screening) or ongoing malignancy other than cutaneous Kaposi's sarcoma (KS), basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma. Individuals with cutaneous KS are eligible, but must not have received any systemic therapy for KS within 30 days of Baseline/Day 1 and must not be anticipated to require systemic therapy during the study~* Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic or antifungal therapy within 30 days prior to Baseline/Day 1~* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements~* Participation in any other clinical trial (including observational trials) without prior approval from the sponsor is prohibited while participating in this trial~* Individuals receiving ongoing therapy with any of the disallowed medications listed in the protocol, including drugs not to be used with FTC, RPV and/or TAF; or individuals with any known allergies to the excipients of FTC/RPV/TAF~Note: Other Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FTC/RPV/TAF (Type: EXPERIMENTAL): FTC/RPV/TAF plus FTC/RPV/TDF placebo for at least 96 weeks.
- FTC/RPV/TDF (Type: ACTIVE_COMPARATOR): FTC/RPV/TDF plus FTC/RPV/TAF placebo for at least 96 weeks.
- Open Label Extension Phase (Type: EXPERIMENTAL): After the Week 96 visit is completed, participants will be given the option to receive open label FTC/RPV/TAF for up to an additional 48 weeks. In countries where FTC/RPV/TAF is not yet commercially available, participants will be given the option to receive open-label FTC/RPV/TAF, and attend visits every 12 weeks until FTC/RPV/TAF becomes commercially available, or until Gilead Sciences elects to discontinue the study, whichever occurs first.

Based on this trial design, predict the completion outcome and termination type (if applicable).